Research
Click on a title below to read more or get full articles in pdf format.
Published Journal Articles
Examining Anti-Cancer Effects of Immune-12 on GBM Cells
Glioblastoma (GBM) remains one of the most lethal and treatment-resistant cancers, underscoring the urgent need for novel therapeutic strategies. Marine-derived nutraceuticals offer a promising avenue due to their unique and myriad bioactive compounds. Immune-12 is an orally available marine organism-derived product that has shown preliminary evidence of anticancer activity in the published literature. Now, our team is conducting a comprehensive investigation …
Anti-inflammatory Activity of Sea Cucumber Supplements
A human food supplement (SeaCare (R)) composed of dried extracts from specific varieties of holothurians (sea cucumbers) and a sea plant has been found to have anti-inflammatory activity in both sexes of two strains of rats. It is slightly less active than aspirin (w/w) against the acute carrageenan-induced paw inflammation, but without the gastrotoxicity of aspirin. It is also active against adjuvant-induced polyarthritis in rats on a daily dose schedule
A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients With Untreated Asymptomatic Myeloma
Patients with smoldering multiple myeloma (MM) may remain asymptomatic (ASx) for variable amounts of time and are therefore typically monitored without treatment. Chemoprevention trials using thalidomide found prohibitive toxicity and longer follow up is needed for early systemic treatment with lenalidomide/ dexamethasone of high risk ASxMM. Based on encouraging preclinical data with bioactive food supplements in MM curcumin (Blood 2003), resveratrol (Blood 2006), and a component of green tea extract (Blood 2006) many patients are already using these agents without definitive proof of efficacy or safety. Preclinically,
Clinical Trials
Australia Clinical Trials Update
📣 ANZCTR Clinical Trial Update: IMMUNE‑12 Now Recruiting
We’re pleased to share that the Phase 2 clinical trial of IMMUNE‑12 for high‑grade gliomas (GBM) is actively recruiting participants at multiple sites in Australia…
Interested in Clinical Trial Participation?
Patients, Health Care Professionals and Researchers interested in participating in our clinical trials can contact the clinical trial sites for eligibility criteria and enrollment information.
USA Clinical Trials
We recently updated our projected timeline for US based clinical trials for Investigational Product Immune12 which will be done in association with our ongoing FDA reviews and approvals.
Australia Clinical Trials
PMB announces the provisional approval of our Phase 2 clinical trial aimed at investigating the efficacy of Immune-12 in treating Glioblastoma Multiforme (GBM) in Australia…
Registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number ACTRN12624001484538p, this trial will involve 60 patients and marks a significant step in our global research efforts… Patient recruitment is now underway…
As we collaborate with esteemed Australian clinical researchers, we are dedicated to developing a robust protocol that leverages local expertise to enhance treatment outcomes for GBM….